Acorda Therapeutics develops therapies for neurological disorders. The company markets Ampyra for multiple sclerosis and Inbrija for Parkinsons disease. It also markets Ampyra as Fampyra globally. The product pipeline includes Cimaglermin alfa, in Phase 1 trials for neurological injury and heart function. The company has a collaboration with Biogen for Ampyra development. Acorda was incorporated in 1995 and is headquartered in Pearl River, New York.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |